Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05183490 · ClinicalTrials.gov registry record · Phase 1
R-MVST Cells for Treatment of Viral Infections
A Phase 1 study of Cytomegalovirus Infections and BK Virus Infection, sponsored by Columbia University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT05183490 is a Phase 1 study of Cytomegalovirus Infections and BK Virus Infection that is actively recruiting participants, run by Columbia University. The registered enrollment target is 36 participants, below the 201-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05183490, a Phase 1 study of Cytomegalovirus Infections and BK Virus Infection, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective is to determine the safety and feasibility of administering R-MVST cells to patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV), adenovirus (ADV) or BK virus. R-MVST cells will be generated on-demand from the closest partially human leukocyte antigen (HLA)-matched (minimum haploidentical) healthy donors or from the original allo-transplant donor if available. The investigator will closely monitor the recipients for potential toxicities including graft-versus-host disease (GVHD) post-infusion. Secondary objectives are to determine the effect of R-MVST infusion on viral load, possible recovery of antiviral immunity post-infusion and for evidence of clinical responses and overall survival. Recipients will be monitored for secondary graft failure at day 28 post R-MVST infusion.
Conditions Studied
Interventions
- DRUG Rapidly generated virus specific T (R-MVST) cells
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-05-03 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05183490
The ClinicalTrials.gov registry entry for NCT05183490 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (82% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Cytomegalovirus Infections appearing as the primary indexed condition, and to 1 intervention - of which Rapidly generated virus specific T (R-MVST) cells is the first listed.
NCT05183490 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05183490 about?
NCT05183490 is a clinical study titled "R-MVST Cells for Treatment of Viral Infections". The primary objective is to determine the safety and feasibility of administering R-MVST cells to patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV), adenovirus (ADV) or BK virus. R-MVST cells will be generated on-demand f...
What is the current status of trial NCT05183490?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2022-05-03. Estimated completion is 2026-12.
What conditions does trial NCT05183490 study?
This clinical trial studies the following conditions: Cytomegalovirus Infections, BK Virus Infection, Adenovirus, Epstein-Barr Virus Infections.
What interventions are being tested in trial NCT05183490?
The interventions under investigation include: Rapidly generated virus specific T (R-MVST) cells (DRUG).
Who is sponsoring clinical trial NCT05183490?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05183490 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytomegalovirus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
RECRUITING · Phase 1
-
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
RECRUITING · Phase 1
-
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation
ACTIVE NOT RECRUITING · Phase 1
-
Viral Specific T-Lymphocytes to Treat Adenovirus or CMV
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults
COMPLETED · Phase 1
-
A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.